Pharsight

Drugs that contain Atorvastatin Calcium; Ezetimibe

1. Liptruzet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5969156 ORGANON Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Jul, 2016

(7 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5846966 ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Sep, 2013

(10 years ago)

US5846966

(Pediatric)

ORGANON Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors
Mar, 2014

(10 years ago)

US5686104 ORGANON Stable oral CI-981 formulation and process of preparing same
Nov, 2014

(9 years ago)

US5686104

(Pediatric)

ORGANON Stable oral CI-981 formulation and process of preparing same
May, 2015

(8 years ago)

USRE42461 ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Oct, 2016

(7 years ago)

US5969156

(Pediatric)

ORGANON Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
Jan, 2017

(7 years ago)

USRE42461

(Pediatric)

ORGANON Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
Apr, 2017

(7 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) May 03, 2016

Market Authorisation Date: 03 May, 2013

Treatment: For the treatment of primary hyperlipidemia, mixed hyperlipidemia or homozygous familial hypercholesterolemia

Dosage: TABLET;ORAL

More Information on Dosage

LIPTRUZET family patents

Family Patents